Shopping Cart 0
Cart Subtotal
USD 0

A1M Pharma AB - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

A1M Pharma AB (A1M Pharma) is a developer of a medical application for the diagnosis and treatment of pre-eclampsia and acute renal damage. The company develops and commercializes drug candidate for the diagnosis and treatment of pre-eclampsia (pandemic poisoning) and acute renal injury. It offers products such as ROSgard based on A1M (alpha-1-microglobulin), an endogenous protein with properties that captures and eliminates toxic substances from the cells metabolism. A1M Pharma's A1M helps to prevent and ameliorate some of the damage caused by oxidative stress and inflammation; and develops novel diagnostic test for preeclampsia based on the biomarker fetal hemoglobin. The company also develops treatments for kidney damage. It also provides constitute therapeutic or diagnostic tools for various conditions and illnesses in animals and humans. A1M Pharma is headquartered in Lund, Sweden.

A1M Pharma AB-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

A1M Pharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

A1M Pharma AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

A1M Pharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

A1M Pharma AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

A1M Pharma AB, Medical Devices Deals, 2012 to YTD 2018 9

A1M Pharma AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

A1M Pharma AB, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

A1M Pharma Partnered with Clinical Trial Consultants 11

A1M Pharma Enters into Agreement with Research Toxicology Centre 12

A1M Pharma Enters into Research Agreement with CSL Behring 13

A1M Pharma Enters into Rresearch Agreement with Fred Hutchinson Cancer Research Centre 14

A1M Pharma Expands Agreement with European Pharmaceutical Company 15

A1M Pharma Enters into Partnership with Truly Translational 16

NeuroVive Pharmal And A1M Pharma Enter Into Research Agreement 17

Equity Offering 18

A1M Pharma Plans to Raise USD10.5 Million in Rights Offering of Shares 18

A1M Pharma Plans to Raise USD13.82 Million in Public Offering of Shares 19

A1M Pharma Raises USD5 Million in Rights Offering of Shares 20

A1M Pharma Raises USD3.7 Million in Rights Offering of Shares 21

A1M Pharma Raises USD3.61 Million in Rights Offering of Shares 22

A1M Pharma AB-Key Competitors 23

A1M Pharma AB-Key Employees 24

A1M Pharma AB-Locations And Subsidiaries 25

Head Office 25

Other Locations & Subsidiaries 25

Recent Developments 26

Corporate Communications 26

Aug 14, 2018: A1M Pharma names Tobias Larsson Agervald as Chief Medical Officer 26

Product News 27

02/10/2017: A1M Pharma has successfully conducted large scale manufacturing of the active substance in ROSGard and initiates GLP toxicology studies 27

Clinical Trials 28

Jun 12, 2017: A1M Pharma announces progress in the preclinical development of ROSGard 28

Mar 29, 2017: A1M Pharma: ROSGard shows strong protective effect against renal damage in connection with radiation therapy in a preclinical long-term study 29

Appendix 30

Methodology 30

About GlobalData 30

Contact Us 30

Disclaimer 30


List Of Figure

List of Figures

A1M Pharma AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

A1M Pharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

A1M Pharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

A1M Pharma AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

A1M Pharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

A1M Pharma AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

A1M Pharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

A1M Pharma AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

A1M Pharma AB, Medical Devices Deals, 2012 to YTD 2018 9


List Of Table

List of Tables

A1M Pharma AB, Pharmaceuticals & Healthcare, Key Facts 2

A1M Pharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

A1M Pharma AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

A1M Pharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

A1M Pharma AB, Deals By Therapy Area, 2012 to YTD 2018 8

A1M Pharma AB, Medical Devices Deals, 2012 to YTD 2018 9

A1M Pharma AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

A1M Pharma Partnered with Clinical Trial Consultants 11

A1M Pharma Enters into Agreement with Research Toxicology Centre 12

A1M Pharma Enters into Research Agreement with CSL Behring 13

A1M Pharma Enters into Rresearch Agreement with Fred Hutchinson Cancer Research Centre 14

A1M Pharma Expands Agreement with European Pharmaceutical Company 15

A1M Pharma Enters into Partnership with Truly Translational 16

NeuroVive Pharmal And A1M Pharma Enter Into Research Agreement 17

A1M Pharma Plans to Raise USD10.5 Million in Rights Offering of Shares 18

A1M Pharma Plans to Raise USD13.82 Million in Public Offering of Shares 19

A1M Pharma Raises USD5 Million in Rights Offering of Shares 20

A1M Pharma Raises USD3.7 Million in Rights Offering of Shares 21

A1M Pharma Raises USD3.61 Million in Rights Offering of Shares 22

A1M Pharma AB, Key Competitors 23

A1M Pharma AB, Key Employees 24

A1M Pharma AB, Subsidiaries 25

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

A1M Pharma AB, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

A1M Pharma AB (A1M Pharma) is a developer of a medical application for the diagnosis and treatment of pre-eclampsia and acute renal damage. The company develops and commercializes drug candidate for the diagnosis and treatment of pre-eclampsia (pandemic poisoning) and acute renal injury. It offers products such as ROSgard based on A1M (alpha-1-microglobulin), an endogenous protein with properties that captures and eliminates toxic substances from the cells metabolism. A1M Pharma's A1M helps to prevent and ameliorate some of the damage caused by oxidative stress and inflammation; and develops novel diagnostic test for preeclampsia based on the biomarker fetal hemoglobin. The company also develops treatments for kidney damage. It also provides constitute therapeutic or diagnostic tools for various conditions and illnesses in animals and humans. A1M Pharma is headquartered in Lund, Sweden.

A1M Pharma AB-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

A1M Pharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

A1M Pharma AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

A1M Pharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

A1M Pharma AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

A1M Pharma AB, Medical Devices Deals, 2012 to YTD 2018 9

A1M Pharma AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

A1M Pharma AB, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

A1M Pharma Partnered with Clinical Trial Consultants 11

A1M Pharma Enters into Agreement with Research Toxicology Centre 12

A1M Pharma Enters into Research Agreement with CSL Behring 13

A1M Pharma Enters into Rresearch Agreement with Fred Hutchinson Cancer Research Centre 14

A1M Pharma Expands Agreement with European Pharmaceutical Company 15

A1M Pharma Enters into Partnership with Truly Translational 16

NeuroVive Pharmal And A1M Pharma Enter Into Research Agreement 17

Equity Offering 18

A1M Pharma Plans to Raise USD10.5 Million in Rights Offering of Shares 18

A1M Pharma Plans to Raise USD13.82 Million in Public Offering of Shares 19

A1M Pharma Raises USD5 Million in Rights Offering of Shares 20

A1M Pharma Raises USD3.7 Million in Rights Offering of Shares 21

A1M Pharma Raises USD3.61 Million in Rights Offering of Shares 22

A1M Pharma AB-Key Competitors 23

A1M Pharma AB-Key Employees 24

A1M Pharma AB-Locations And Subsidiaries 25

Head Office 25

Other Locations & Subsidiaries 25

Recent Developments 26

Corporate Communications 26

Aug 14, 2018: A1M Pharma names Tobias Larsson Agervald as Chief Medical Officer 26

Product News 27

02/10/2017: A1M Pharma has successfully conducted large scale manufacturing of the active substance in ROSGard and initiates GLP toxicology studies 27

Clinical Trials 28

Jun 12, 2017: A1M Pharma announces progress in the preclinical development of ROSGard 28

Mar 29, 2017: A1M Pharma: ROSGard shows strong protective effect against renal damage in connection with radiation therapy in a preclinical long-term study 29

Appendix 30

Methodology 30

About GlobalData 30

Contact Us 30

Disclaimer 30


List Of Figure

List of Figures

A1M Pharma AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

A1M Pharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

A1M Pharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

A1M Pharma AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

A1M Pharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

A1M Pharma AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

A1M Pharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

A1M Pharma AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

A1M Pharma AB, Medical Devices Deals, 2012 to YTD 2018 9


List Of Table

List of Tables

A1M Pharma AB, Pharmaceuticals & Healthcare, Key Facts 2

A1M Pharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

A1M Pharma AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

A1M Pharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

A1M Pharma AB, Deals By Therapy Area, 2012 to YTD 2018 8

A1M Pharma AB, Medical Devices Deals, 2012 to YTD 2018 9

A1M Pharma AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

A1M Pharma Partnered with Clinical Trial Consultants 11

A1M Pharma Enters into Agreement with Research Toxicology Centre 12

A1M Pharma Enters into Research Agreement with CSL Behring 13

A1M Pharma Enters into Rresearch Agreement with Fred Hutchinson Cancer Research Centre 14

A1M Pharma Expands Agreement with European Pharmaceutical Company 15

A1M Pharma Enters into Partnership with Truly Translational 16

NeuroVive Pharmal And A1M Pharma Enter Into Research Agreement 17

A1M Pharma Plans to Raise USD10.5 Million in Rights Offering of Shares 18

A1M Pharma Plans to Raise USD13.82 Million in Public Offering of Shares 19

A1M Pharma Raises USD5 Million in Rights Offering of Shares 20

A1M Pharma Raises USD3.7 Million in Rights Offering of Shares 21

A1M Pharma Raises USD3.61 Million in Rights Offering of Shares 22

A1M Pharma AB, Key Competitors 23

A1M Pharma AB, Key Employees 24

A1M Pharma AB, Subsidiaries 25

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

A1M Pharma AB, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.